SynAct Pharma: Bringing resolution therapy to inflammatory diseases - Redeye

Redeye initiates coverage of SynAct Pharma, a biotech company advancing a novel approach to controlling inflammation through resolution rather than traditional antagonism. Its lead candidate, resomelagon, is undergoing a phase IIb trial in rheumatoid arthritis designed to optimize the probability of success, with full recruitment expected by Q4 2025. Strong results could spur a partnering deal in 2026, representing a large upside to the current share price.

Länk till analysen i sin helhet: https://www.redeye.se/research/1061934/synact-pharma-bringing-resolution-therapy-to-inflammatory-diseases?utm_source=finwire&utm_medium=RSS